When was entrectinib launched in China?

Entrectinib is a revolutionary broad-spectrum anti-cancer drug that will be launched in China on July 29, 2022. On this day, China's National Medical Products Administration (NMPA) officially announced that Roche's entrectinib has been approved for marketing. This is undoubtedly an important milestone for Chinese cancer patients.

Entrectinib is now available in China and included in the medical insurance system, and patients can purchase it domestically. However, it is quite expensive, costing about 20,000 yuan. For specific price information and medical insurance reimbursement details, patients are advised to consult their local hospital pharmacy for accurate information. In comparison, the price of foreign generic entrectinib drugs is relatively affordable, especially the generic drugs produced in Laos, which only cost about one to two thousand yuan. It is worth mentioning that the ingredients of these generic drugs are basically the same as those of the original drugs.

Enrectinib is a dual-target inhibitor targeting NTRK and ROS1. Its unique mechanism of action allows it to have significant therapeutic effects on a variety of solid tumors. The indications approved in China are NTRK fusion-positive locally advanced and metastatic solid tumors, which means that patients for whom traditional treatments are ineffective or ineffective have new treatment options.

It is worth mentioning that the launch of entrectinib in China also marks that China has made important progress in the field of anti-cancer drug development and treatment. With the continuous advancement of medical technology and the successive launch of innovative drugs, Chinese cancer patients will have access to more advanced and effective treatments, thereby improving survival rates and quality of life.

In short, the launch of entrectinib in China is good news worth celebrating. It not only brings new hope to patients, but also injects new impetus into the development of China's anti-cancer cause. We look forward to more innovative drugs being released in the future and making greater contributions to human health.